24th Sep 2021 07:47
(Alliance News) - AstraZeneca PLC on Friday said that the PROpel phase three trial for Lynparza has achieved its primary endpoint of radiographic progression-free survival in men with metastatic castration-resistant prostate cancer, compared to standard-of-care abiraterone.
PROpel is a randomised, double-blind, multi-centre phase three trial testing the efficacy, safety, and tolerability of Lynparza against placebo when given in addition to abiraterone in men with mCRPC.
Interim analysis by the Independent Data Monitoring Committee concluded that the trial met the primary endpoint in men which had not received treatment in the first-line setting including new hormonal agents or chemotherapy.
The Anglo-Swedish drugmaker also noted that the trial showed a trend towards improved overall survival; however as the data is still immature, the trial will continue to assess the factor as a key secondary endpoint.
Another secondary endpoint for the trial is the time to first subsequent anticancer therapy or death.
Prostate cancer is known as the second most common cancer in men, with five-year survival remaining low despite an increase in the number of available treatments.
"Today, men with metastatic castration-resistant prostate cancer have limited options in the 1st-line setting, and sadly often the disease progresses after initial treatment with current standards of care. These exciting results demonstrate the potential for Lynparza with abiraterone to become a new 1st-line option for patients regardless of their biomarker status and reach a broad population of patients living with this aggressive disease," said Susan Galbraith, executive vice president of Oncology R&D at Astra.
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca